Abstract Details

Title The Impact of Social Capital on Patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-069

Objective To investigate the effect of social capital (SC) on the physical and psychological impact of multiple sclerosis (MS).

Background SC refers to the resources derived from the cooperation between individuals and groups. SC partially explains how social conditions influence health and mortality. The effect of SC on the outcomes of people with MS (pwMS) has not been explored before.

Design/Methods A cross-sectional study was conducted among pwMS at The Royal London Hospital, London, UK. Participants completed an online survey including the MS Impact Scale (MSIS-29), the Hospital Anxiety and Depression Scale (HADS), the self-reported Expanded Disability Status Scale and a SC question set. The SC questionnaire assessed personal relationships, social support networks, civic engagement, and trust and cooperative norms. Kendall's tau correlation test was performed to measure the association between SC and MSIS-29. Multiple linear regressions were conducted to find the best outcome prediction model. Normality, multicollinearity and independence of errors were checked for each model.

Results

236 patients participated in the study. Median age was 43.5 years (IQR 35-52). 168 (71.19%) were female and 164 (69.49%) had relapsing-remitting MS. Abnormal scores for HADS (≥8/21) were seen in 133 (56.35%) and 72 (30.51%) patients, respectively. Median scores were 23.72 (IQR 8.75-57.5) for the physical and 38.89 (IQR 16.67-55.56) for the psychological scales of the MSIS-29. The total SC and personal relationships domain scores were significantly associated with MSIS-29 physical scores (τb=0.09, p=0.02 and 0.21, p<0.001, respectively). All SC domains except social support networks (τb=0.01, p=0.39) were significantly associated with MSIS-29 psychological scores.

Conclusions Higher scores on certain SC domains were associated with lower self-rated physical and psychological impact of MS. Emerging evidence on SC and MS should be translated into interventions for health-promoting purposes.

Authors/Disclosures
Saul Reyes, MD (The Royal London Hospital) PRESENTER	Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIIB. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Ifat Vigiser (Tel Aviv Medical Center)	Ifat Vigiser has nothing to disclose.
	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.

��ɫ��

��ɫ��